Abilify (Aripiprazole): Off-Label Uses and Special Considerations

Off-Label Uses and Dosing

Abilify may be used at doses of 5 mg orally or intramuscularly for the management of delirium in adult cancer patients, particularly when less sedation is desired, as recommended by the American Society of Clinical Oncology 1, 2
Aripiprazole has been studied in the context of maintaining abstinence from alcohol, though acamprosate has stronger evidence for this indication, according to the National Institute for Health and Care Excellence 3

Lower doses of Abilify are recommended for elderly patients, those with hepatic impairment, or poor metabolizers of cytochrome P450 2D6, as suggested by the American Geriatrics Society 1, 2
Common side effects of Abilify include headache, agitation, anxiety, insomnia, dizziness, and drowsiness, with a moderate strength of evidence, as reported by the Annals of Oncology 1, 2
Abilify is less likely to cause extrapyramidal symptoms (EPS) than first-generation antipsychotics, though the risk increases at higher doses, with a high strength of evidence, as reported by the American Academy of Neurology 1, 2

Abilify may be particularly useful when a less sedating antipsychotic is desired, with a low strength of evidence, as suggested by the American Psychiatric Association 1, 2
In combination therapy scenarios, such as with cariprazine, lower doses of each medication may be used to maintain efficacy while reducing side effects, with a moderate strength of evidence, as reported by the European Psychiatric Association 4

Aripiprazole has a lower sedation profile compared to other antipsychotics, such as olanzapine and quetiapine, making it a preferable option when sedation is a concern, as noted in clinical guidelines from the American College of Clinical Pharmacology 5
When treating patients at risk for arrhythmias, aripiprazole is favored as it has not been associated with QTc prolongation or torsade de pointes, according to the European Society of Cardiology 6
For patients with delirium, aripiprazole may offer benefit in symptomatic management with less sedation, as recommended by the American Psychiatric Association 5

The American Psychiatric Association recommends that aripiprazole may be added to a long-acting antipsychotic, such as paliperidone, in patients with schizophrenia who have not responded to monotherapy, with a starting dose of 5 mg per day and gradual titration based on response and side effects 7, 8
Aripiprazole can be particularly useful for reducing negative symptoms when added to another antipsychotic, with a mean difference of -0.41 (95% CI -0.79 to -0.03, p = 0.036) in eight studies (N = 532) 7
The use of aripiprazole in combination with clozapine is one of the most studied and promising combinations, potentially allowing for a reduction in clozapine dose, decrease in side effects, and reduction in residual symptoms 8

The National Institute of Mental Health recommends starting with a dose of 5 mg per day when adding aripiprazole to another antipsychotic, with gradual titration based on clinical response and side effects 8
The target dose is typically between 10 and 15 mg per day, although the approved therapeutic range is 10 to 30 mg per day 8

The American Psychiatric Association recommends documenting the patient's current symptomatology and clinical state before starting antipsychotic polytherapy, and following up after initiation 8
If the patient does not improve, antipsychotic polytherapy should be reduced to monotherapy or other combinations should be explored 8
If the patient improves and reaches a stable state, consideration should be given to slowly and cautiously returning to monotherapy, as many patients seem to be able to tolerate it and may only benefit from polytherapy during symptomatic exacerbations 8

The American College of Psychiatry and other guideline societies recommend aripiprazole as a suitable option for treating negative symptoms in schizophrenia, with a minimum effective dose of 10 mg/day 9
The 2025 INTEGRATE guidelines from The Lancet Psychiatry recommend aripiprazole as a suitable option when switching antipsychotics for persistent negative symptoms, with a dose of 10 mg/day 9
For negative symptoms specifically, cariprazine or aripiprazole are recommended as suitable switch options, with low-dose amisulpride reserved only for cases where positive symptoms are not a concern 9

Before attributing persistent negative symptoms solely to primary schizophrenia pathology, systematically evaluate and address persistent positive symptoms, depressive symptoms, substance misuse, social isolation, medical illness, and side-effects of antipsychotic medication including extrapyramidal symptoms, sedation, and marked weight gain leading to sleep apnea 9

Before starting aripiprazole, obtain baseline measures including BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, and liver function 9
Follow-up monitoring should include metabolic parameters at regular intervals, as aripiprazole has a favorable metabolic profile but monitoring remains essential 9